1. Home
  2. LCNB vs EDIT Comparison

LCNB vs EDIT Comparison

Compare LCNB & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LCNB Corporation

LCNB

LCNB Corporation

HOLD

Current Price

$16.11

Market Cap

238.1M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.54

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCNB
EDIT
Founded
1877
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.1M
206.0M
IPO Year
1999
2016

Fundamental Metrics

Financial Performance
Metric
LCNB
EDIT
Price
$16.11
$2.54
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$4.92
AVG Volume (30 Days)
20.2K
1.7M
Earning Date
04-30-2026
06-08-2026
Dividend Yield
5.43%
N/A
EPS Growth
68.04
37.50
EPS
1.63
N/A
Revenue
$6,445,000.00
$31,937,000.00
Revenue This Year
$8.50
N/A
Revenue Next Year
$3.66
N/A
P/E Ratio
$9.95
N/A
Revenue Growth
N/A
132.64
52 Week Low
$13.34
$0.91
52 Week High
$17.89
$4.54

Technical Indicators

Market Signals
Indicator
LCNB
EDIT
Relative Strength Index (RSI) 33.73 61.33
Support Level $15.24 $2.42
Resistance Level $16.44 $2.76
Average True Range (ATR) 0.46 0.18
MACD -0.13 0.06
Stochastic Oscillator 9.01 75.13

Price Performance

Historical Comparison
LCNB
EDIT

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: